Pulmonary Artery Hypertension in Children Living with Sickle Cell Anaemia
DOI:
https://doi.org/10.17140/HROJ-6-151Keywords:
Sickle cell anaemia; Pulmonary artery hypertension ChildrenAbstract
Pulmonary artery hypertension (PAH) ultimately leads to straining of the right ventricle and increases the risk of heart failure in
affected patients. Its clinical presentation is similar to that of many other diseases thus delaying the diagnosis until the disease is far
advanced. It remains one of the leading causes of death in adults with sickle cell anaemia (SCA) worldwide. It confers a high risk
of death with two-year mortality rates as high as 40-50% even at modest elevation of pulmonary artery pressure. Median survival
age after detection of the disease is said to be 25.6-months. Early detection of elevated pulmonary artery pressure in childhood and
appropriate intervention by optimization of anti-haemolytic therapy may prevent the progression of this complication. The current
writes up is a review of literatures on pulmonary artery hypertension among children with sickle cell anaemia. This will give information
which will aid early diagnosis and treatment of pulmonary artery hypertension among children with sickle cell anaemia. This
will ultimately improve the quality of life of children with sickle cell anaemia and reduce morbidity and mortality from the disease
in adults and children living with sickle cell anaemia.
References
Kato G. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol. 2007; 24(3): 159-170. doi: 10.1080/08880010601185892
Klings ES. Pulmonary hypertension of sickle cell disease: More than just another lung disease. Am J Hematol. 2008; 83(1): 4-5. doi: 10.1002/ajh.21083
Liem RI, Young LT, Thompson AA. Tricuspid regurgitant jet velocity is associated with hemolysis in children and adults with sickle cell disease evaluated for pulmonary hypertension. Haematologica. 2007; 92: 1549-1552. doi: 10.3324/haematol.11576
Collombati R, Maschietto N, Varotto E, et al. Pulmonary hypertension in sickle cell disease children under 10 years of age. Br J Haematol. 2010; 150(5): 601-609. doi: 10.1111/j.1365- 2141.2010.08269.x
Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics. 2008; 121(4): 777-782. doi: 10.1542/peds.2007-0730
Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: Association with hemolysis and hemoglobin oxygen desaturation. Haematologica. 2009; 94: 340-347. doi: 10.3324/ haematol.13812
Gordeuk VR, Minniti CP, Nouraie M, et al. Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica. 2011; 96(1): 33-40. doi: 10.3324/ haematol.2010.030767
Sedrak A, Rao SP, Miller ST, Hekmat V, Rao M. A prospective appraisal of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol. 2009; 31: 97-100. doi: 10.1097/ MPH.0b013e31818e5343
Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velociy, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 21 Animasahun BA et al 2006; 47(7): 907-913. doi: 10.1002/pbc.20791
Suell MN, Benzold LI, Okcu MF, Mahoney DH, Shardonofsky F, Mueller BU. Increased pulmonary artery pressure among adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2005; 27(12): 654-658. doi: 10.1097/01.mph.0000194022.17968.bf
Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in sickle cell disease. Pediatr Blood Cancer. 2006; 47(7): 907-913. doi: 10.1002/pbc.20791
Qureshi N, Joyce JJ, Qi N, Chang RK. Right ventricular abnormalities in sickle cell anemia: Evidence of a progressive increase in pulmonary vascular resistance. J Pediatr. 2006; 149(1): 23-27. doi: 10.1016/j.jpeds.2005.12.055
Lee MT, Rosenzweig EB, Cairo MS. Pulmonary hypertension in sickle cell disease. Clini Adv Hematol Oncol. 2007; 5(8): 645-653.
Aliyu ZY, Gorduek V, Sachdev V, et al. Prevalence and risk factors for pulmonary systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol. 2008; 83(6): 485-490. doi: 10.1002/ajh.21162
Dosunmu AO, Balogun TM, Adeyeye OO, et al. Prevalence of pulmonary hypertension in sickle cell anaemia patients of a tertiary hospital in Nigeria. Niger Med J. 2014; 55(2): 161-165. doi: 10.4103/0300-1652.129661
Voskaridou E, Tsetsos G, Tsoutsias A, Spyropoulou E, Christoulas D, Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and corellation with serum N-terminal pro-brain naturetic peptide concentrations. Haematologica. 2007; 92: 738-743. doi: 10.3324/haematol.11136
Waxman AB. Exercise physiology and pulmonary arterial hypertension. Prog Cardiovasc Dis. 2012; 55(2): 172-179. doi: 10.1016/j.pcad.2012.07.003
Eidem BW, Cetta F, O’Leary PW. Echocardiography in pediatric and adult congenital heart disease. Philadelphia, USA: Lippincott Williams & Wilkins; 2009.
Barst R, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: A comparison between children and adults. Eur Respir J. 2011; 37(3): 665-677. doi: 10.1183/09031936.00056110
Fredric DB, Richard AP, Julie RI ER. Gellis & Kagans Current Pediatric Therapy. 15th ed. Philadelphia, USA: Elsevier Health Sciences; 1995.
Gladwin MT, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9): 886-895. doi: 10.1056/NEJMoa035477
Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endotheliun receptor antagoniosts for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol. Review | Volume 6 | Number 1| 2009; 147: 737-743. doi: 10.1111/j.1365-2141.2009.07906.x
Lin EE, Rodgers GP, Gladwin MT. Hemolytic anaemia associated with pulmonary hypertension in sickle cell disease. Curr Hematol Rep. 2005; 4(2): 117-125.
Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med. 2003; 9(2): 131-138.
Gladwin MT, Sachdev V, Jison M, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9): 886-895. doi: 10.1056/NEJMoa035477 Submit your article to this journal | https://openventio.org/submit-manuscript/ Review | Volume 6 | Number 1| Animasahun BA et al
D’Alto M, Romeo E, Argiento P, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assesment of pulmonary hypertension. Int J Cardiol. 2013; 168(4): 4058-4062. doi: 10.1016/j.ijcard.2013.07.005
Machado RF GM. Chronic sickle cell lung disease: New insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005; 129(4): 449-464. doi: 10.1111/j.1365-2141.2005.05432.x
Ruan CH, Dixon RA, Wilerson JT, Ke-He Ruan. Prostacyclin therapy for pulmonary aterial hypertension. Tex Hear Inst J. 2010; 37(4): 391-399.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.